ZYME (Zymeworks) Other Financing: $4.94 Mil (TTM As of Mar. 2026)


ZYME Zymeworks Inc ZYME
66 GF Score
Price $26.31
GF Value $24.21
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zymeworks Other Financing?

Zymeworks ZYME +2.47% 66 Other Financing is $4.94 Mil as of Mar. 2026. GuruFocus rates ZYME with a GF Score™ of 66/100 and a GF Value™ of $24.21 (Fairly Valued). The stock has 5 warning signs investors should review.

Zymeworks's Other Financing for the three months ended in Mar. 2026 was $4.94 Mil.

Zymeworks's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $4.94 Mil.

Zymeworks Other Financing Historical Data

* Premium members only.

The historical data trend for Zymeworks's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zymeworks Other Financing Chart

Zymeworks Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.03 1.06 5.79 9.63 18.15

Zymeworks Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 4.94
ZYME
66GF Score
Zymeworks Inc ZYME
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zymeworks Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $4.94 Mil mean?
Zymeworks (ZYME) has a Other Financing of $4.94 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Zymeworks and its competitors.
Is Zymeworks' Other Financing too high?
Zymeworks' current Other Financing is $4.94 Mil. Overall, Zymeworks has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Other Financing compare to SRPT and BCAX?
Zymeworks' Other Financing of $4.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Zymeworks and its competitors. Zymeworks's current Other Financing is $4.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Fairly Valued. The stock's GF Value™ is $24.21, compared to a current price of $26.31 — trading 8.7% above its estimated fair value. The current Other Financing is $4.94 Mil. Zymeworks' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Zymeworks (ZYME), the current Other Financing is $4.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of $26.31 is trading 8.7% above its estimated GF Value™ of $24.21. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for ZYME:

  • Other Financing: $4.94 Mil
  • GF Value™: $24.21 vs. price of $26.31 (8.7% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score

Get the complete analysis for ZYME

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.31
Price
$24.21
GF Value